(HealthDay News) — For overweight and obese participants, trans-resveratrol (tRES) and hesperetin (HESP) coformulation increases glyoxalase 1 (Glo1) expression and produces improvements in metabolic and vascular health, according to a study published in Diabetes.
Mingzhan Xue, MD, PhD, from the University of Warwick in the United Kingdom, and colleagues screened bioactive compounds for Glo1 inducer activity in a functional reporter assay, confirmed hits in cell culture, and evaluated an optimized Glo1 inducer formulation in a randomized crossover trial involving 29 overweight and obese participants.
The researchers found that clinically-achieved concentrations of tRES and HESP synergized to increase Glo1 expression. tRES-HESP coformulation increased expression and activity of Glo1 in highly overweight participants, and decreased plasma methylglyoxal and total body methylglyoxal-protein glycation.
In addition, tRES-HESP coformulation was associated with decreased fasting and postprandial plasma glucose, increased oral glucose insulin sensitivity index, and improved arterial dilation. Decreases were seen in vascular inflammation marker soluble intercellular adhesion molecule-1 in all participants.
“In previous clinical evaluations, tRES and HESP individually were ineffective,” the researchers wrote. “tRES-HESP coformulation could be a suitable treatment for improved metabolic and vascular health in overweight and obese populations.”
Several authors are employees of Unilever, which partially funded the study.